Clinical pharmacology of a new ureidopenicillin: Bay K 49999.
A new semisynthetic ureidopenicillin (Bay K 4999) demonstrates favorably in vitro antibacterial efficacy against human-pathogenic gram-negative rods in comparison to mezlocillin and azlocillin. A comparative paramcokinetic study was done with 10 test subjects after 30 min intravenous infusion of 4.0 g of Bay K and mezlocillin, respectively. The serum concentration course during a period of 10 h showed an open three-compartment model for both antibiotics. The urine recovery of Bay K 4999 during 24 h was only 32.6 +/- 4.3% of the applied dose. In three test subjects with normal renal function, the average renal clearance of Bay K was 61.0, the total serum clearance was 409.2 ml/min/1.73 m2. 31 patients were treated with a daily dose of 3 x 1.0--2.0 g Bay K for severe bronchopulmonary, UTI and cholangiogenic infections. The therapeutic results were good; the relatively high number of side effects should be further investigated in animal studies and require more clinical experience.
D000328:Adult; D001390:Azlocillin / Q000031:analogs & derivatives*; D001424:Bacterial Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D048289:Imidazolidines; D007700:Kinetics; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010406:Penicillins / Q000378:metabolism / Q000494:pharmacology*; D013997:Time Factors
D048289:Imidazolidines; D010406:Penicillins; D001390:Azlocillin; C017976:furazlocillin